NDLTD Global ETD Search
  • Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 74
  • 37
  • 23
  • 11
  • 10
  • 7
  • 6
  • 6
  • 4
  • 2
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 209
  • 61
  • 32
  • 27
  • 25
  • 24
  • 23
  • 23
  • 22
  • 18
  • 17
  • 16
  • 16
  • 15
  • 15
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.

Search results

Showing 1 to 10 of 209 (0.046 seconds)

Spelling suggestions: "subject:"agonist"" "subject:"gonist""

1

Investigations of derivatives of 14#beta#-amino-7,8-dihydromorphinone

Nieland, Nick January 1998 (has links)
No description available.
547
Opioid; Agonist; Heroin
2

The #gamma#-aminobutyrate/benzodiazepine receptor from pig brain : Purification and characterization

Kirkness, E. F. January 1986 (has links)
No description available.
572
Neuroreceptor agonist binding
3

Studies on dopamine and opioid receptor subtypes : Their interactions in the C.N.S

Rooney, K. F. January 1987 (has links)
No description available.
615.1
Dopamine agonist pharmacology
4

Neuronale Modulation der Einfluss von Agonisten und inverser Agonisten auf das Cannabinoidsystem einer hippocampalen Primärkultur /

Klink, Oliver, January 2007 (has links)
Hohenheim, Univ., Diss., 2007.
Endocannabinoide. Zellkultur. Agonist.
5

Synthese von nicht-natürlichen Aminosäuren und Aminosäure-Konjugaten : pharmakologisch interessante Bausteine für Peptidmimetika /

Kirschbaum, Bettina. January 1996 (has links) (PDF)
Univ., Diss.--Stuttgart, 1996.
6

Design, parallel synthesis and biological evaluation of agonists for the G-protein coupled human orphan receptor BRS-3

Weber, Dirk. January 2003 (has links) (PDF)
München, Techn. Univ., Diss., 2003.
G-Proteine Rezeptor Agonist
7

Group I mGlu receptors : desensitization properties and modulation of cerebrocortical glutamate release

Reid, Morag January 2000 (has links)
No description available.
612
Synaptosomes; Agonist; Arachidonic acid
8

Functional aspects of neuronal nicotinic receptor diversity

Covernton, Patrick John O'Neill January 1999 (has links)
No description available.
615.1
Oocytes; Acetylcholine; Agonist response
9

Initial Flare Symptoms Resulting from Use of LHRH Agonist in Metastatic Prostate Cancer: Systematic Review and Economic Evaluation

Poon, Yeesha 03 January 2011 (has links)
Background LHRH agonists decrease tumour size/activity by suppressing testosterone in prostate cancer; however, initial injection causes testosterone surge that triggers flare symptoms. Anti-androgen given with agonist may reduce/avoid flare symptoms. When LHRH antagonist/blocker is introduced, testosterone suppression is immediate, but there is uncertainty about significance of flare symptoms without anti-androgen. Objective Systematic review compared significance of flare symptoms avoided and cost utility analysis using modelling comparing incremental value of blocker (degarelix) OR agonist (goserelin)+anti-androgen (bicalutamide) VERSUS agonist alone in prostate cancer patients. Outcome Incremental cost/QALY of bone pain as flare symptom between treatments Results Thirteen studies were reviewed. There was no standard definition for flare symptoms or data on LHRH antagonist versus other treatments on flare. From societal perspective, goserelin+bicalutamide was dominated over goserelin alone and similarly, from public perspective, goserelin+bicalutamide had favourable cost effectiveness profile against goserelin. Conclusion With bone pain as clinical endpoint, LHRH agonist+anti-androgen had favourable cost-effectiveness profile compared to goserelin.
prostate cancer
LHRH agonist
0992
10

Initial Flare Symptoms Resulting from Use of LHRH Agonist in Metastatic Prostate Cancer: Systematic Review and Economic Evaluation

Poon, Yeesha 03 January 2011 (has links)
Background LHRH agonists decrease tumour size/activity by suppressing testosterone in prostate cancer; however, initial injection causes testosterone surge that triggers flare symptoms. Anti-androgen given with agonist may reduce/avoid flare symptoms. When LHRH antagonist/blocker is introduced, testosterone suppression is immediate, but there is uncertainty about significance of flare symptoms without anti-androgen. Objective Systematic review compared significance of flare symptoms avoided and cost utility analysis using modelling comparing incremental value of blocker (degarelix) OR agonist (goserelin)+anti-androgen (bicalutamide) VERSUS agonist alone in prostate cancer patients. Outcome Incremental cost/QALY of bone pain as flare symptom between treatments Results Thirteen studies were reviewed. There was no standard definition for flare symptoms or data on LHRH antagonist versus other treatments on flare. From societal perspective, goserelin+bicalutamide was dominated over goserelin alone and similarly, from public perspective, goserelin+bicalutamide had favourable cost effectiveness profile against goserelin. Conclusion With bone pain as clinical endpoint, LHRH agonist+anti-androgen had favourable cost-effectiveness profile compared to goserelin.
prostate cancer
LHRH agonist
0992

Page generated in 0.0507 seconds